
Martí JM 🌐
@martijim7
🧠🌍🗽 Global medical manager Alzheimer's | Also @InstitutOstrom @EconomiaED_ | @KingsCollegeLon | #LifeSciences #SciDip #LaRespostaLiberal
ID: 772024424
https://es.linkedin.com/in/martijimenezmausbach 21-08-2012 18:35:49
14,14K Tweet
2,2K Followers
1,1K Following






✍🏻 «¿Qué proporción del debate público está abordando hoy cuestiones como la mejora del capital humano, el acceso empresarial a los mercados de capitales o las barreras regulatorias al crecimiento del tamaño empresarial?» Martí JM 🌐 sobre #productividad economiadigital.es/ideas/tapa-euf…




I am thrilled to share the Alzheimer’s Disease Drug Development Pipeline: 2025 with our fabulous colleague Jeffrey Cummings Very glad to see more diverse targets beyond anti-amyloid drugs. Looking forward pipeline 2026! Thanks The National Institute on Aging (NIA) alz-journals.onlinelibrary.wiley.com/doi/epdf/10.10…




LAUNCH DAY 🚀 Today I’m launching a new podcast, Hard Drugs, with Jacob Trefethen (Jacob Trefethen) Our first episode is about lenacapavir — a new HIV drug that blocks infections with an efficacy rate of nearly 100%, and which could completely change the fight against HIV worldwide.



Why has fertility suddenly crashed everywhere all at once? There are many factors, which vary across all world regions & over time. But we should also recognise the collapse of coupling. Always open to new data & ideas! 🙂 Graph by John Burn-Murdoch



Brad Loncar People age. Inflammation, glucose control, and other atherosclerosis pathways evolve. Even with PCSK9 knocked out with laser precision (long term data) other drivers (e.g., Lp(a), triglyceride-rich lipoproteins) may still accelerate disease. So: cool tool, not a silver bullet.
